These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21488860)

  • 1. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F
    Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Scandurra M; Mian M; Greiner TC; Rancoita PM; De Campos CP; Chan WC; Vose JM; Chigrinova E; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Montes-Moreno S; Piris MA; Facchetti F; Tucci A; Nomdedeu JF; Lazure T; Lambotte O; Uccella S; Pinotti G; Pruneri G; Martinelli G; Young KH; Tibiletti MG; Rinaldi A; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Fabbri A; Gozzetti A; Rigacci L
    Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
    Chae YS; Kim JG; Sohn SK; Moon JH; Kim SN; Lee SJ; Park TI; Lee MH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):571-7. PubMed ID: 19629486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Front-line management of diffuse large B cell lymphoma.
    Cabanillas F
    Curr Opin Oncol; 2010 Nov; 22(6):642-5. PubMed ID: 20811278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
    Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
    Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
    Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
    Akhtar S; Maghfoor I
    N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab CHOP for successful management of diffuse large B-cell lymphoma of the ovary.
    Ahbeddou N; Fetohi M; Khanoussi BE; Errihani H
    Arch Gynecol Obstet; 2011 May; 283(5):1173-4. PubMed ID: 20957380
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary colonic lymphoma: an analysis of 74 cases with localized large-cell lymphoma.
    Tang TC; Kuo MC; Chang H; Dunn P; Wang PN; Wu JH; Lin TL; Hung YS; Kuo TT; Shih LY
    Eur J Haematol; 2011 Jul; 87(1):28-36. PubMed ID: 21535155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of the International Prognostic Index in the rituximab era.
    Tay K; Tai D; Tao M; Quek R; Ha TC; Lim ST
    J Clin Oncol; 2011 Jan; 29(1):e14; author reply e15. PubMed ID: 21115864
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
    Yahalom J
    J Clin Oncol; 2010 Sep; 28(27):4105-7. PubMed ID: 20713874
    [No Abstract]   [Full Text] [Related]  

  • 16. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
    Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
    [No Abstract]   [Full Text] [Related]  

  • 17. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP and rituximab in elderly patients.
    Portlock CS
    Curr Oncol Rep; 2002 Sep; 4(5):414. PubMed ID: 12162916
    [No Abstract]   [Full Text] [Related]  

  • 19. Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
    Czuczman MS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-46-52. PubMed ID: 23570100
    [No Abstract]   [Full Text] [Related]  

  • 20. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.